Patent Issued for Anordrin compositions and methods for treating diseases (USPTO 11911397).
In: Women's Health Weekly, 2024-03-21, S. 1816-1816
serialPeriodical
Zugriff:
A patent has been issued for Anordrin compositions and methods for treating diseases. The patent discusses the role of estrogen in regulating RNA transcription and cell proliferation, as well as the use of selective estrogen receptor modulators (SERMs) in treating postmenopausal symptoms. The patent also mentions the use of anordrin, an estrogen receptor antagonist, in combination with other agents such as tamoxifen and raloxifene to reduce side effects and treat cancer. The inventors propose administering anordrin and other agents sequentially or simultaneously to achieve the desired therapeutic effects. The patent is assigned to Zhejiang Jiachi Development Pharmaceuticals Ltd. in China. [Extracted from the article]
Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Anordrin compositions and methods for treating diseases (USPTO 11911397).
|
---|---|
Zeitschrift: | Women's Health Weekly, 2024-03-21, S. 1816-1816 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-7240 (print) |
Schlagwort: |
|
Sonstiges: |
|